Lakefront Biotherapeutics Stock (NASDAQ:LKFT)
Previous Close
$28.04
52W Range
$25.68 - $37.78
50D Avg
$28.63
200D Avg
$30.58
Market Cap
$1.81B
Avg Vol (3M)
$193.07K
Beta
0.12
Div Yield
-
LKFT Company Profile
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.